Antibody-mediated protection through cross-reactivity introduces a fungal heresy into immunological dogma.
作者信息
Casadevall Arturo, Pirofski Liise-anne
机构信息
Department of Microbiology and Immunology, Albert Einstein College of Medicine, 1300 Morris Park Ave, Bronx, NY 10461, USA.
出版信息
Infect Immun. 2007 Nov;75(11):5074-8. doi: 10.1128/IAI.01001-07. Epub 2007 Aug 20.
Abstract
摘要
相似文献
1
Antibody-mediated protection through cross-reactivity introduces a fungal heresy into immunological dogma.
Infect Immun. 2007 Nov;75(11):5074-8. doi: 10.1128/IAI.01001-07. Epub 2007 Aug 20.
2
Immunoglobulins in defense, pathogenesis, and therapy of fungal diseases.
Cell Host Microbe. 2012 May 17;11(5):447-56. doi: 10.1016/j.chom.2012.04.004.
3
Vaccines against fungal infections.
Crit Rev Microbiol. 1987;14(3):229-71. doi: 10.3109/10408418709104440.
4
Fungal vaccines: real progress from real challenges.
Lancet Infect Dis. 2008 Feb;8(2):114-24. doi: 10.1016/S1473-3099(08)70016-1.
5
[Immunohistochemistry diagnosis of fungal infections].
Rev Hosp Clin Fac Med Sao Paulo. 1998 Jul-Aug;53(4):184-8.
6
Polysaccharide-containing conjugate vaccines for fungal diseases.
Trends Mol Med. 2006 Jan;12(1):6-9. doi: 10.1016/j.molmed.2005.11.003. Epub 2005 Nov 23.
7
Killer antibodies in fungal infections.
Res Immunol. 1998 May-Jun;149(4-5):334-43; discussion 523. doi: 10.1016/s0923-2494(98)80757-8.
8
Nanoparticle-Based Mycosis Vaccine.
Methods Mol Biol. 2017;1625:169-211. doi: 10.1007/978-1-4939-7104-6_13.
9
Immunity to fungi: editorial overview.
Res Immunol. 1998 May-Jun;149(4-5):277-81. doi: 10.1016/s0923-2494(98)80751-7.
10
Immunological aspects of fungal pathogenesis.
Eur J Clin Microbiol Infect Dis. 1990 Aug;9(8):567-79. doi: 10.1007/BF01967211.
引用本文的文献
1
Human-Fungal Pathogen Interactions from the Perspective of Immunoproteomics Analyses.
Int J Mol Sci. 2024 Mar 20;25(6):3531. doi: 10.3390/ijms25063531.
2
Humoral Immunity Against Aspergillus fumigatus.
Mycopathologia. 2023 Oct;188(5):603-621. doi: 10.1007/s11046-023-00742-0. Epub 2023 Jun 8.
3
Protective role of host complement system in infection.
Front Immunol. 2022 Sep 23;13:978152. doi: 10.3389/fimmu.2022.978152. eCollection 2022.
4
Protective Efficacy of Lectin-Fc(IgG) Fusion Proteins In Vitro and in a Pulmonary Aspergillosis In Vivo Model.
J Fungi (Basel). 2020 Oct 27;6(4):250. doi: 10.3390/jof6040250.
5
Effects of immune suppression in murine models of disseminated Candida glabrata and Candida tropicalis infection and utility of a synthetic peptide vaccine.
Med Mycol. 2019 Aug 1;57(6):745-756. doi: 10.1093/mmy/myy122.
6
Conservation of Intracellular Pathogenic Strategy among Distantly Related Cryptococcal Species.
Infect Immun. 2018 Jun 21;86(7). doi: 10.1128/IAI.00946-17. Print 2018 Jul.
7
Characterization of the antifungal functions of a WGA-Fc (IgG2a) fusion protein binding to cell wall chitin oligomers.
Sci Rep. 2017 Sep 22;7(1):12187. doi: 10.1038/s41598-017-12540-y.
8
Spp.: Virulence Factors and Immune-Evasion Strategies.
Mediators Inflamm. 2017;2017:5313691. doi: 10.1155/2017/5313691. Epub 2017 May 2.
9
Innate host defenses against Cryptococcus neoformans.
J Microbiol. 2016 Mar;54(3):202-11. doi: 10.1007/s12275-016-5625-7. Epub 2016 Feb 27.
10
Antibodies generated against Streptococci protect in a mouse model of disseminated aspergillosis.
J Immunol. 2015 May 1;194(9):4387-96. doi: 10.4049/jimmunol.1401940. Epub 2015 Mar 27.
本文引用的文献
1
An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo.
Infect Immun. 2007 Nov;75(11):5085-94. doi: 10.1128/IAI.00278-07. Epub 2007 Jul 2.
2
A comparison of the pulmonary inflammatory potential of different components of yeast cell wall.
J Toxicol Environ Health A. 2007 Jul;70(13):1116-24. doi: 10.1080/15287390701212224.
3
Natural antibody and complement mediate neutralization of influenza virus in the absence of prior immunity.
J Virol. 2007 Apr;81(7):3487-94. doi: 10.1128/JVI.02128-06. Epub 2007 Jan 3.
4
Human domain antibodies against virulence traits of Candida albicans inhibit fungus adherence to vaginal epithelium and protect against experimental vaginal candidiasis.
J Infect Dis. 2007 Jan 1;195(1):149-57. doi: 10.1086/509891. Epub 2006 Nov 20.
5
Vaccinations with recombinant variants of Aspergillus fumigatus allergen Asp f 3 protect mice against invasive aspergillosis.
Infect Immun. 2006 Sep;74(9):5075-84. doi: 10.1128/IAI.00815-06.
6
A fungicidal monoclonal antibody protects against murine invasive candidiasis.
Infect Immun. 2006 May;74(5):3042-5. doi: 10.1128/IAI.74.5.3042-3045.2006.
7
A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis.
Clin Infect Dis. 2006 May 15;42(10):1404-13. doi: 10.1086/503428. Epub 2006 Apr 12.
8
Active immunization against Pneumocystis carinii with a recombinant P. carinii antigen.
Infect Immun. 2006 Apr;74(4):2446-8. doi: 10.1128/IAI.74.4.2446-2448.2006.
9
Complement and Fc function are required for optimal antibody prophylaxis against Pneumocystis carinii pneumonia.
Infect Immun. 2006 Jan;74(1):390-3. doi: 10.1128/IAI.74.1.390-393.2006.
10
Specific antibody can prevent fungal biofilm formation and this effect correlates with protective efficacy.
Infect Immun. 2005 Oct;73(10):6350-62. doi: 10.1128/IAI.73.10.6350-6362.2005.
Zotero 插件